Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Homerun, But A Base Hit For Teva's Laquinimod

This article was originally published in The Pink Sheet Daily

Executive Summary

Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.

You may also be interested in...

Teva Faces Laquinimod Setback After High Dose Linked To CV Events

Teva will discontinue higher doses of laqunimod in two ongoing studies for multiple sclerosis after cardiovascular events were experienced in eight patients. Trials will continue with a lower dose.

Teva Pins Long-Term Hopes In MS On The Return Of Laquinimod

Teva has ambitions to file in 2018 after the Phase III CONCERTO trial reads out in 2017. Firm is studying a higher dose of the drug and relying on a different primary endpoint, hoping to show stronger efficacy over a Phase III trial that failed in 2011.

Third Trial For Teva’s Laquinimod Hinges On SPA From FDA

Teva will initiate a third clinical trial testing the oral multiple sclerosis drug laquinimod after finalizing a special protocol assessment with FDA.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts